Design Therapeutics Inc
Uždarymo kaina
14.64 -0.48
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
14.47
Max
14.64
Pajamos | -2.5M -20M |
|---|---|
Pelnas, tenkantis vienai akcijai | -0.32 |
Darbuotojai | 55 |
EBITDA | -4.5M -22M |
Kitas uždarbis | 2026-11-03 |
|---|
Rinkos kapitalizacija | 205M 947M |
|---|---|
Ankstesnė atidarymo kaina | 15.12 |
Ankstesnė uždarymo kaina | 14.64 |
Design Therapeutics Inc Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Susijusios naujienos
Akcijų palyginimas
Kainos pokytis
Design Therapeutics Inc Prognozė
Finansinės naujienos
Pardavimo ir administravimo išlaidos
Veiklos sąnaudos
Ikimokestinis pelnas
Pardavimai
Pardavimo savikaina
Bendrasis pelnas iš pardavimo
Skolų palūkanų išlaidos
EBITDA
Veiklos pelnas
$
Apie bendrovę Design Therapeutics Inc
Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.